Drugs for Leishmaniasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 103)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Lidocaine |
Approved, Vet_approved |
Phase 4 |
|
137-58-6 |
3676 |
Synonyms:
2-(Diethylamino)-2',6'-acetoxylidide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-2ETN-2MePhAcN
a-Diethylamino-2,6-dimethylacetanilide
ALGRX 3268
ALGRX-3268
ALPHACAINE
alpha-Diethylamino-2,6-dimethylacetanilide
ANESTACON
Astrazeneca brand OF lidocaine
Dalcaine
Dentipatch
Dilocaine
EMBOLEX
IONTOCAINE
Jenapharm brand OF lidocanine hydrochloride
L-Caine
Lidocaina
Lidocaína
LIDOCAINE
Lidocaine carbonate
Lidocaine carbonate (2:1)
Lidocaine hydrocarbonate
Lidocaine hydrochloride
Lidocaine monoacetate
Lidocaine monohydrochloride
|
Lidocaine monohydrochloride, monohydrate
Lidocaine sulfate (1:1)
Lidocainum
LIDOCATON
Lidoderm
LIDOPEN
Lignocaine
LIGNOCAINE HCL
LIGNOSTAB
LMX 4
Novocol brand OF lidocaine hydrochloride
NSC-40030
Octocaine
ORAQIX
Strathmann brand OF lidocaine hydrochloride
VAGISIL
Xylesthesin
Xylocaine
Xylocaine®
Xylocitin
XYLODASE
Xyloneural
XYLOTOX
ZTLIDO
Α-diethylamino-2,6-dimethylacetanilide
|
|
2 |
|
Amphotericin B |
Approved, Investigational |
Phase 4 |
|
1397-89-3 |
5280965 |
Synonyms:
ABBR amb
ABELCET
Ambisome
Amfotericina b
AMOPHOTERICIN B
AMPH-b
Amphocil
AMPHO-MORONAL
Amphortericin b
Amphotec
AMPHOTERCIN B
Amphotericin
AMPHOTERICIN B
Amphotericin b cholesterol dispersion
Amphotericin b colloidal dispersion
|
AMPHOTERICIN B LIPID COMPLEX
AMPHOTERICIN B LIPOSOMAL COMPLEX
Amphotericine b
AMPHOTÉRICINE B
Amphotericinum b
AMPHOTERICITIN B
AMPHOTREICIN B
AMPOTERICIN B
APT370
C-AMB
FUNGILIN
FUNGILIN IN ORABASE
Fungizone
Liposomal amphotericin b
NSC-527017
|
|
3 |
|
Deoxycholic acid |
Approved |
Phase 4 |
|
83-44-3 |
222528 |
Synonyms:
(3a,5a,12a)-3,12-DIHYDROXYCHOLAN-24-Oate
(3a,5a,12a)-3,12-DIHYDROXYCHOLAN-24-Oic acid
(3a,5b,12a)-3,12-Dihydroxycholan-24-Oate
(3a,5b,12a)-3,12-Dihydroxycholan-24-Oic acid
(3alpha,5alpha,12alpha)-3,12-DIHYDROXYCHOLAN-24-Oate
(3ALPHA,5ALPHA,12ALPHA)-3,12-DIHYDROXYCHOLAN-24-OIC ACID
(3alpha,5beta,12alpha)-3,12-Dihydroxycholan-24-Oate
(3alpha,5beta,12alpha)-3,12-Dihydroxycholan-24-Oic acid
(3Α,5α,12α)-3,12-dihydroxycholan-24-Oate
(3Α,5α,12α)-3,12-dihydroxycholan-24-Oic acid
(3Α,5β,12α)-3,12-dihydroxycholan-24-Oate
(3Α,5β,12α)-3,12-dihydroxycholan-24-Oic acid
12beta-Isomer deoxycholic acid
3a,12a-Dihydroxy-5b-cholanate
3a,12a-Dihydroxy-5b-cholanic acid
3alpha,12alpha-Dihydroxy-5beta-cholanate
3alpha,12alpha-Dihydroxy-5beta-cholanic acid
3beta-Isomer deoxycholic acid
3Α,12α-dihydroxy-5β-cholanate
3Α,12α-dihydroxy-5β-cholanic acid
5alpha-Isomer deoxycholic acid
5b-Cholanic acid-3a,12a-diol
5b-Deoxycholate
5b-Deoxycholic acid
7a-Deoxycholate
7a-Deoxycholic acid
7alpha-Deoxycholate
7alpha-Deoxycholic acid
7-Deoxycholate
7-Deoxycholic acid
7Α-deoxycholate
7Α-deoxycholic acid
Acid, 5alpha-isomer deoxycholic
Acid, choleic
Acid, deoxycholic
Acid, desoxycholic
Acid, dihydroxycholanoic
|
Acid, lagodeoxycholic
ATX-101
ATX-101|DCA|deoxycholate
Choleic acid
Cholerebic
Cholorebic
Degalol
Deoxycholatate
Deoxycholate
Deoxy-cholate
Deoxycholate, sodium
Deoxycholatic acid
Deoxycholic acid
Deoxy-cholic acid
Deoxycholic acid, 12beta isomer
Deoxycholic acid, 12beta-isomer
Deoxycholic acid, 3beta isomer
Deoxycholic acid, 3beta-isomer
Deoxycholic acid, 5alpha isomer
Deoxycholic acid, 5alpha-isomer
Deoxycholic acid, disodium salt
Deoxycholic acid, magnesium (2:1) salt
Deoxycholic acid, monoammonium salt
Deoxycholic acid, monopotassium salt
Deoxycholic acid, monosodium salt
Deoxycholic acid, sodium salt, 12beta-isomer
Desoxycholate
Desoxycholic acid
Desoxycholsaeure
Desoxycholsäure
Dihydroxycholanoic acid
DWJ211
DWJ-211
KYBELLA
Lagodeoxycholic acid
NSC-8797
Sodium deoxycholate
|
|
4 |
|
Meglumine antimoniate |
Experimental, Investigational |
Phase 4 |
|
133-51-7 |
|
Synonyms:
Antimoniato de meglumina
Glucantim
Glucantime
|
Meglumine antimonate
Meglumine antimoniate
|
|
5 |
|
Antimony Sodium Gluconate |
|
Phase 4 |
|
|
|
6 |
|
Anthelmintics |
|
Phase 4 |
|
|
|
7 |
|
Anesthetics |
|
Phase 4 |
|
|
|
8 |
|
Anti-Bacterial Agents |
|
Phase 4 |
|
|
|
9 |
|
Amebicides |
|
Phase 4 |
|
|
|
10 |
|
Liposomal amphotericin B |
|
Phase 4 |
|
|
|
11 |
|
Amphotericin B, deoxycholate drug combination |
|
Phase 4 |
|
|
|
12 |
|
Gastrointestinal Agents |
|
Phase 4 |
|
|
|
13 |
|
Paromomycin |
Approved, Investigational |
Phase 3 |
|
1263-89-4, 7542-37-2 |
165580 |
Synonyms:
(1R,2R,3S,4R,6S)-4,6-Diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2-amino-2-deoxy-alpha-D-glucopyranoside
(1R,2R,3S,4R,6S)-4,6-Diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-b-L-idopyranosyl)-b-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2-amino-2-deoxy-a-D-glucopyranoside
(1R,2R,3S,4R,6S)-4,6-Diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-β-L-idopyranosyl)-β-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2-amino-2-deoxy-α-D-glucopyranoside
Aminosidin
Aminosidine
ANTIBIOTIC 503-3
ANTIBIOTIC SF 767B
beta-D-Glucopyranosyl-isomer paromomycin
Catenulin
Cheminova brand OF paromomycin sulfate
Crestomycin
Estomycin
Gabbromycin
Humatin
Hydroxymycin
Monarch brand OF paromomycin sulfate
MONOMYCIN
Monomycin a
Neomycin e
PARAMICINA
Paramomycin
Paramomycin sulfate
|
Paramomycin sulphate
Parke davis brand OF paromomycin sulfate
Paromomicina
PAROMOMYCIN
Paromomycin I
Paromomycin phosphate
Paromomycin sulfate
Paromomycin sulfate (1:1)
Paromomycin sulfate (2:5)
Paromomycin, beta D glucopyranosyl isomer
Paromomycin, beta-D-glucopyranosyl-isomer
Paromomycine
Paromomycinum
Paucimycin
Paucimycinum
Pfizer brand OF paromomycin sulfate
Phosphate, paromomycin
PRM
R 400
R-400
Sulfate, paromomycin
Zygomycin a1
|
|
14 |
|
Carbamide peroxide |
Approved |
Phase 2, Phase 3 |
|
124-43-6 |
|
Synonyms:
Carbamide peroxide
Hydrogen peroxide carbamide
Urea dioxide
|
Urea hydrogen peroxide
Urea peroxide
|
|
15 |
|
Sargramostim |
Approved, Investigational |
Phase 3 |
|
123774-72-1 |
|
Synonyms:
B1 61.012
B1-61012
LEUKINE
RECOMBINANT GM-CSF
Recombinant human granulocyte-macrophage colony stimulating factor
|
rGM-CSF
RHU GM-CSF
RHU-GM-CSF
SARGRAMOSTIM
|
|
16 |
|
Aluminum sulfate |
Approved |
Phase 2, Phase 3 |
|
10043-01-3 |
|
Synonyms:
Aluminium sulfate
Aluminium sulfate anhydrous
Aluminum sulfate anhydrous
|
Aluminum sulphate anhydrous
Dialuminum sulfate
Dialuminum trisulfate
|
|
17 |
|
Pentoxifylline |
Approved, Investigational |
Phase 2, Phase 3 |
|
6493-05-6 |
4740 |
Synonyms:
Agapurin
BL-191
BL-191|Trental®
C04AD03
EHT0201
NEOTREN MR
NSC-637086
Oxpentifylline
Pentoxifilina
|
Pentoxifyllin
Pentoxifylline
Pentoxifyllinum
Pentoxil
Torental
Trental
TRENTAL 100
TRENTAL 400
|
|
18 |
|
Imiquimod |
Approved, Investigational |
Phase 3 |
|
99011-02-6 |
57469 |
Synonyms:
1-Isobutyl-1H-imidazo(4,5-c)quinolin-4-amine
1-Isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline
Aldara
Aldara®|R837|S-26308|Zyclara®
Imiquimod
Imiquimod acetate
|
Imiquimodum
R 837
R-837
S-26308
ZARTRA
Zyclara
|
|
19 |
|
Tocopherol |
Approved, Investigational |
Phase 3 |
|
1406-66-2 |
|
Synonyms:
Methyltocols
tocoferol
tocoferoles
|
|
|
20 |
|
BCG vaccine |
Approved, Investigational |
Phase 2, Phase 3 |
|
|
|
Synonyms:
BACILLUS CALMETTE GUERIN VACCINE
BACILLUS CALMETTE GUÉRIN VACCINE
Bacillus Calmette–Guérin (BCG) vaccine
|
Bacillus calmette-guerin live antigen, unspecified substrain
BCG
BCG vaccine
|
|
21 |
|
Azithromycin |
Approved |
Phase 2, Phase 3 |
|
83905-01-5 |
447043 |
Synonyms:
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-b-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
Azadose
AZASITE
Azenil
Azifast
Azigram
Azimakrol
Azithramycine
AZITHROMYCIN
AZITHROMYCIN ANHYDROUS
Azithromycin dihydrate
AZITHROMYCIN HYDRATE
Azithromycin monohydrate
Azithromycin pfizer brand
Azithromycine
Azithromycinum
Azitrocin
Azitromicina
Azitromin
AZYTER
Azythromycin
Bayer brand OF azithromycin dihydrate
CLAMELLE
CP 62993
|
CP-62,993
CP-62993
Dihydrate, azithromycin
Funk brand OF azithromycin dihydrate
Goxal
Hemomycin
Lesvi brand OF azithromycin dihydrate
Mack brand OF azithromycin dihydrate
Monohydrate, azithromycin
Pfizer brand OF azithromycin
Pfizer brand OF azithromycin dihydrate
Pharmacia brand OF azithromycin dihydrate
Sumamed
SUNAMED
Toraseptol
Ultreon
Vinzam
Vita brand OF azithromycin dihydrate
XZ 405
XZ 450
XZ-450
Zentavion
Zithromax
Zitromax
Zmax
|
|
22 |
|
Fluconazole |
Approved, Investigational |
Phase 3 |
|
86386-73-4 |
3365 |
Synonyms:
2-(2,4-DIFLUOROPHENYL)-1,3-di(1H-1,2,4-triazol-1-yl)propan-2-ol
2,4-Difluoro-a,a-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol
2,4-Difluoro-alpha,alpha-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol
2,4-Difluoro-α,α-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol
AbZ brand OF fluconazole
Aliud brand OF fluconazole
Alpharma brand OF fluconazole
Apo fluconazole
Apo-fluconazole
Apotex brand OF fluconazole
Armstrong brand OF fluconazole
Béagyne
Betapharm brand OF fluconazole
Biozole
CANESTEN ORAL
Chemia brand OF fluconazole
CT Arzneimittel brand OF fluconazole
CT-Arzneimittel brand OF fluconazole
Diflucan
DIFLUCAN IN SODIUM CHLORIDE
DIFLUCAN ONE
Difluconazole
Effik brand OF fluconazole
Elazor
Fluc hexal
Flucobeta
FlucoLich
Fluconazol
Fluconazol abz
Fluconazol al
Fluconazol isis
|
Fluconazol ratiopharm
Fluconazol stada
Fluconazol von CT
Fluconazole
Fluconazole capsules
FLUCONAZOLE IN SODIUM CHLORIDE
Fluconazol-isis
Fluconazol-ratiopharm
Fluconazolum
Flunazul
Fungata
Hexal brand OF fluconazole
Lavisa
Lesvi brand OF fluconazole
Lichtenstein brand OF fluconazole
Loitin
Mack brand OF fluconazole
Neofomiral
Oxifungol
Pfizer brand OF fluconazole
Pfleger brand OF fluconazole
Ratiopharm brand OF fluconazole
SAT brand OF fluconazole
Silanes brand OF fluconazole
Solacap
Stada brand OF fluconazole
Triflucan
UK-49858
Vita brand OF fluconazole
Zonal
|
|
23 |
|
Nitric Oxide |
Approved |
Phase 3 |
|
10102-43-9 |
145068 |
Synonyms:
(.)NO
(NO)(.)
[NO]
EDRF
Endogenous nitrate vasodilator
Endothelium-derived nitric oxide
Endothelium-derived relaxing factor
HYDROXYAMINE
INOmax
INOmax®|nitric oxide|nitrogen monoxide
Mononitrogen monoxide
Monoxide, mononitrogen
Monoxide, nitrogen
Monoxido de nitrogeno
Monóxido de nitrógeno
Monoxyde d'azote
Nitrate vasodilator, endogenous
NITRIC OXIDE
Nitric oxide, endothelium derived
Nitric oxide, endothelium-derived
Nitrogen monooxide
|
Nitrogen monoxide
Nitrogen oxide
Nitrogen protoxide
Nitrosyl
Nitrosyl hydride
Nitrosyl radical
Nitroxide radical
Nitroxyl
NO
NO(.)
OHM-11771
Oxide, nitric
Oxido de nitrogeno(II)
óxido de nitrógeno(II)
Oxido nitrico
óxido nítrico
Oxyde azotique
Oxyde nitrique
Stickstoff(II)-oxid
Stickstoffmonoxid
Vasodilator, endogenous nitrate
|
|
24 |
|
DL-alpha-Tocopherol |
Approved, Experimental, Investigational, Nutraceutical, Vet_approved |
Phase 3 |
|
59-02-9, 10191-41-0 |
2116 14985 |
Synonyms:
(-)-a-Tocopherol
(-)-Α-tocopherol
(+)-2R,4’R,8’R-α-Tocopherol
(+)-2R,4'R,8'R-alpha-Tocopherol
(+)-2R,4'R,8'R-α-Tocopherol
(+)-alpha-Tocopherol
(+)-a-Tocopherol
(+)-α-Tocopherol
(±)-α-tocopherol
(2R)-2,5,7,8-TETRAMETHYL-2-[(4R,8R)-4,8,12-TRIMETHYLTRIDECYL]CHROMAN-6-OL
(2R)-3,4-Dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-ol
(2R,4’R,8’R)-α-Tocopherol
(2R,4'R,8'R)-alpha-Tocopherol
(2R,4'r,8'r)-a-Tocopherol
(2R,4'R,8'R)-α-Tocopherol
(all-R)-alpha-Tocopherol
(all-R)-α-Tocopherol
(R,R,R)-alpha-Tocopherol
(R,R,R)-a-Tocopherol
(R,R,R)-α-Tocopherol
3,4-Dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-(2R)-2H-1-benzopyran-6-ol
5,7,8-Trimethyltocol
a-D-Tocopherol
all-rac-alpha-tocopherol
Almefrol
ALPHA TOCOPHEROL
alpha-delta-Tocopherol
alpha-D-Tocopherol
alpha-Tocopherol
alpha-Vitamin E
Amino-Opti-E
AQUASOL E
a-Tocopherol
d-alpha-Tocopherol
Daltose
|
D-a-Tocopherol
delta-alpha-Tocopherol
Denamone
DL-5,7,8-trimethyltocol
DL-alpha tocopherol
DL-α-tocopherol
d-α-Tocopherol
E-200 I.U. Softgels
E307
E-Complex-600
E-Ferol
Emipherol
Eprolin
Etamican
E-VIMIN
E-Vitamin succinate
Evitaminum
Gordo-Vite E
NATOPHEROL
Phytogermin
Phytogermine
Profecundin
RRR-alpha-Tocopherol
RRR-alpha-Tocopheryl
TOCOPHEROL
Vitamin e
Vitamin E DL-alpha
Vitamin ea
Vitamin Ealpha
Vitamin Eα
Vitamin Plus E Softgells
Vitec
α-D-Tocopherol
α-Tocopherol
α-Vitamin E
|
|
25 |
|
Molgramostim |
Investigational |
Phase 3 |
|
99283-10-0 |
|
Synonyms:
|
MOLGRAMOSTIM (GENETICAL RECOMBINATION)
SCH-39300
|
|
26 |
|
Tocotrienol |
Investigational |
Phase 3 |
|
6829-55-6 |
9929901 |
Synonyms:
|
27 |
|
Vaccines |
|
Phase 2, Phase 3 |
|
|
|
28 |
|
Immunologic Factors |
|
Phase 3 |
|
|
|
29 |
|
Gentamicins |
|
Phase 3 |
|
|
|
30 |
|
Vitamins |
|
Phase 3 |
|
|
|
31 |
|
Adjuvants, Immunologic |
|
Phase 3 |
|
|
|
32 |
|
Radiation-Protective Agents |
|
Phase 2, Phase 3 |
|
|
|
33 |
|
Phosphodiesterase Inhibitors |
|
Phase 2, Phase 3 |
|
|
|
34 |
|
Platelet Aggregation Inhibitors |
|
Phase 2, Phase 3 |
|
|
|
35 |
|
interferons |
|
Phase 3 |
|
|
|
36 |
|
Tocotrienols |
|
Phase 3 |
|
|
|
37 |
|
Tocopherols |
|
Phase 3 |
|
|
|
38 |
|
Pharmaceutical Solutions |
|
Phase 3 |
|
|
|
39 |
|
Antioxidants |
|
Phase 3 |
|
|
|
40 |
|
Protective Agents |
|
Phase 3 |
|
|
|
41 |
|
Hormones |
|
Phase 3 |
|
|
|
42 |
|
Hormone Antagonists |
|
Phase 3 |
|
|
|
43 |
|
Cytochrome P-450 Enzyme Inhibitors |
|
Phase 3 |
|
|
|
44 |
|
Respiratory System Agents |
|
Phase 3 |
|
|
|
45 |
|
Vasodilator Agents |
|
Phase 3 |
|
|
|
46 |
|
Bronchodilator Agents |
|
Phase 3 |
|
|
|
47 |
|
Anti-Asthmatic Agents |
|
Phase 3 |
|
|
|
48 |
|
Endothelium-Dependent Relaxing Factors |
|
Phase 3 |
|
|
|
49 |
|
Neurotransmitter Agents |
|
Phase 3 |
|
|
|
50 |
|
Pentamidine |
Approved, Investigational |
Phase 2 |
|
100-33-4 |
4735 |
Synonyms:
1,3-Bis(4-amidinophenoxy)pentane
1,5-Bis(4-amidinophenoxy)pentane
4, 4'-Diamidinodiphenoxypentane
4,4'-(1,5-Pentanediylbis(oxy))bis-benzenecarboximidamide
4,4'-(Pentamethylenedioxy)dibenzamidine
4,4'-Diamidinodiphenoxypentane
American pharmaceutical partners brand 1 OF pentamidine isethionate
American pharmaceutical partners brand 2 OF pentamidine isethionate
Aventis brand OF pentamidine isethionate
Diamidine
GlaxoSmithKline brand OF pentamidine isethionate
GNF-PF-3680
JHC Brand OF pentamidine isethionate
Lomidine
MB 800 FREE BASE
MB-800
MB-800 (AS ISETHIONATE)
MB-800 [AS ISETHIONATE]
MB-800 FREE BASE
NebuPent
NEBUPENT [AS ISETHIONATE]
NSC-9921
|
p,P'-(pentamethylenedioxy)dibenzamidine
Pentacarinat
PENTACARINAT [AS ISETHIONATE]
Pentam
PENTAM 300
PENTAM 300 [AS ISETHIONATE]
Pentamide
Pentamidin
PENTAMIDINA
PENTAMIDINDIISETIONAT
PENTAMIDINE
Pentamidine isethionate
PENTAMIDINE ISETIONATE
Pentamidine mesylate
PENTAMIDINUM
PNT
Rhône-poulenc rorer brand OF pentamidine isethionate
RP 2512 FREE BASE
RP-2512
RP-2512 [AS ISETHIONATE]
RP-2512 FREE BASE
Sicor brand OF pentamidine isethionate
|
|
Interventional clinical trials:
(show top 50)
(show all 179)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Point of Care Diagnosis and Treatment With Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India. |
Unknown status |
NCT01566552 |
Phase 4 |
AMBISOME |
2 |
A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL) |
Completed |
NCT01975051 |
Phase 4 |
Mitefosine |
3 |
Low-dose Pentavalent Antimony Treatment of Cutaneous Leishmaniasis in Old Age Patients Infected With Leishmania (Viannia) Braziliensis in Bahia State, Brazil. An Open Uncontrolled Trial. |
Completed |
NCT00818818 |
Phase 4 |
Meglumine antimoniate |
4 |
Safety and Effectiveness of Short-course AmBisome in the Treatment of Post-Kala-azar Dermal Leishmaniasis (PKDL): a Prospective Cohort Study in Bangladesh |
Completed |
NCT03311607 |
Phase 4 |
AmBisome |
5 |
Efficacy and Safety of Amphotericin B Deoxycholate Compared to Meglumine Antimoniate for Treatment of Visceral Leishmaniasis in Brazilian Children |
Completed |
NCT01032187 |
Phase 4 |
Meglumine antimoniate;Amphotericin B-deoxycholate |
6 |
An Open Label Study of RFH Therapy as Treatment for CL Caused by Leishmania Tropica in India |
Completed |
NCT01661296 |
Phase 4 |
Sodium stibogluconate |
7 |
Phase IV Randomized Controlled Clinical Trial to Evaluate the Safety and Efficacy of Low-Dose Pentavalent Antimony Compared to the Standard Dose in Patients With Cutaneous Leishmaniasis Caused by Leishmania (Viannia)Braziliensis |
Completed |
NCT00317980 |
Phase 4 |
Meglumine antimoniate |
8 |
A Phase 4 Study to Expand Access Program While Assessing the Safety and Efficacy of Paromomycin IM Injection in an Outpatient Setting for the Treatment of Visceral Leishmaniasis |
Completed |
NCT00604955 |
Phase 4 |
Paromomycin sulfate |
9 |
Pharmacokinetics of Miltefosine in Children and Adults: Implications for the Treatment of Cutaneous Leishmaniasis in Colombia. |
Completed |
NCT01462500 |
Phase 4 |
Miltefosine |
10 |
Multicentric Efficacy and Safety Study of Antileishmanial Drugs for Treatment of Visceral Leishmaniasis in Brazil |
Terminated |
NCT01310738 |
Phase 4 |
Antimoniate of N-methylglucamine;amphotericin B deoxycholate;Liposomal amphotericin B |
11 |
Phase III Clinical Trial for Mucosal or Mucocutaneous Leishmaniasis. Comparison Between the Standard and Alternative Antimonial Schemes |
Unknown status |
NCT01301937 |
Phase 2, Phase 3 |
Meglumine antimoniate |
12 |
Randomized Clinical Trial of the Efficacy and Tolerability of Oral Miltefosine Versus Parenteral Antimony for the Treatment of Pediatric Cutaneous Leishmaniasis in Colombia |
Unknown status |
NCT00487253 |
Phase 3 |
Miltefosine;Meglumine antimoniate |
13 |
Topical Paromomycin Cream For Bolivian Cutaneous Eishmaniasis: A Controlled Study |
Completed |
NCT03096457 |
Phase 2, Phase 3 |
Paromomycin Sulfate;Pentamidine Isethionate |
14 |
Phase III Clinical Trial for American Tegumentary Leishmaniasis: Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis |
Completed |
NCT01301924 |
Phase 2, Phase 3 |
Meglumine antimoniate |
15 |
A Randomized Trial of Ambisome Monotherapy and Combination of Ambisome and Miltefosine for the Treatment of VL in HIV Positive Patients in Ethiopia Followed by Secondary VL Prophylactic Treatment With Pentamidine. |
Completed |
NCT02011958 |
Phase 3 |
Liposomal Amphotericin B;Miltefosine |
16 |
Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia. |
Completed |
NCT00471705 |
Phase 3 |
Miltefosine;Glucantime® |
17 |
Miltefosine and GM-CSF in Cutaneous Leishmaniasis: a Randomized and Controlled Trial |
Completed |
NCT03023111 |
Phase 3 |
Sbv;Miltefosine plus placebo;Miltefosine plus GM-CSF |
18 |
Randomized, Open-label, Parallel-group, Safety & Efficacy Study to Evaluate Different Combination Treatment Regimens, of Either AmBisome and Paromomycin, AmBisome and Miltefosine, or Paromomycin and Miltefosine Compared With Amphotericin B Deoxycholate (the Standard) Therapy for the Treatment of Acute, Symptomatic Visceral Leishmaniasis (VL). |
Completed |
NCT00696969 |
Phase 3 |
Amphotericin B Deoxycholate;Ambisome + Miltefosine;Ambisome and Paromomycin;Miltefosine and Paromomycin |
19 |
Evaluation of Efficacy of Intra-lesional Injections of Glucantime Once Weekly in Comparison With Twice Weekly in the Treatment of Acute Anthroponotic Cutaneous Leishmaniasis (ACL) |
Completed |
NCT04340128 |
Phase 3 |
Meglumine antimoniate |
20 |
A Randomised, Open-label, Parallel-group, Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens (Co-administration), of AmBisome, Paromomycin and Miltefosine in Visceral Leishmaniasis (VL) |
Completed |
NCT00523965 |
Phase 3 |
amphotericin B deoxycholate;Liposomal Amphotericin B with Miltefosine;Liposomal Amphotericin B and Paromomycin Sulfate;miltefosine + Paromomycin sulfate |
21 |
Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis |
Completed |
NCT03829917 |
Phase 2, Phase 3 |
Miltefosine and Paromomycin;miltefosine;paromomycin |
22 |
An Open Lable Randomised Two -Arm Study to Assess the Safety and Efficacy of Paromomycin Administered Intramuscularly at Two Different Dosing Regimens (14 Days Versus 21 Days) for the Treatment of Indian Visceral Leishmaniasis (VL) |
Completed |
NCT00629031 |
Phase 3 |
Paromomycin |
23 |
A Phase III, Open Label, Randomised, Study of Three Short Course Combination Regimens (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome® Alone for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh |
Completed |
NCT01122771 |
Phase 3 |
Liposomal amphotericin B;liposomal amphotericin B + miltefosine;liposomal amphotericin B + paromomycin;Miltefosine + Paromomycin |
24 |
A Phase III Randomized, Controlled, Clinical Trial to Assess the Safety and Efficacy of Single Infusion of Liposomal Amphotericin B in Patients With Visceral Leishmaniasis |
Completed |
NCT00628719 |
Phase 3 |
Liposomal Amphotericin B;amphotericin B deoxycholate |
25 |
Phase 2 Study Electrothermocauterisation of Afghan Patients With Anthroponotic Cutaneous Leishmaniasis With and Without Pharmaceutical Chlorite Listed in the German Drug Codex (DAC N-055) |
Completed |
NCT00947362 |
Phase 2, Phase 3 |
DAC N-055;saline |
26 |
Replacement of Insecticides to Control Visceral Leishmaniasis |
Completed |
NCT01644682 |
Phase 3 |
|
27 |
A Phase 3 Multicenter, Randomized, Controlled, Clinical Trial to Assess the Safety and Efficacy of Injectable Paromomycin in Patients With Visceral Leishmaniasis |
Completed |
NCT00216346 |
Phase 3 |
Paromomycin sulfate;Amphotericin B |
28 |
Phase 3, Clinical Trials of Drug Against Cutaneous Leishmaniasis |
Completed |
NCT00351520 |
Phase 3 |
Miltefose |
29 |
Randomized Double Blind Clinical Trial of Imiquimod (Aldara) Versus Placebo Used in Combination With Pentavalent Antimony (Glucantime) in Peruvian Cutaneous Leishmaniasis Patients |
Completed |
NCT00257530 |
Phase 3 |
Imiquimod |
30 |
A Multicentre Comparative Trial of Efficacy and Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) Versus Combination of SSG and PM as the First Line Treatment for Visceral Leishmaniasis in Ethiopia, Kenya and Sudan |
Completed |
NCT00255567 |
Phase 3 |
Sodium Stibogluconate;Paromomycin sulphate;SSG and Paromomycin sulphate |
31 |
A Prospective, Multicentric, Randomized, Two Arm, Open Label Phase III Study To Assess Efficacy And Safety Of Infusion Of Amphomul® (Amphotericin B Emulsion) As Compared To Liposomal Amphotericin In Patients Of Visceral Leishmaniasis (Kala Azar) |
Completed |
NCT00876824 |
Phase 3 |
Amphotericin B Lipid emulsion;Liposomal Amphotericin B |
32 |
An Open Label, Phase III, Randomized Controlled, Multicentre Non-Inferiority Trial to Compare Efficacy and Safety of Miltefosine and Paromomycin With SSG and PM Combination for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa |
Completed |
NCT03129646 |
Phase 3 |
Miltefosine;Paromomycin;Sodium stibogluconate |
33 |
A Pivotal, Randomized, Double-blind, Vehicle-controlled Study to Evaluate WR 279,396 and Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia) |
Completed |
NCT00606580 |
Phase 3 |
WR 279,396 topical cream;Paromomycin Alone topical cream;Vehicle placebo cream |
34 |
A Study for Safety and Efficacy of Miltefosine for Treatment of Children and Adolescents With Post-Kala-azar Dermal Leishmaniasis (PKDL) in Bangladesh and Association of Serum Vitamin E and Exposure to Arsenic With PKDL |
Completed |
NCT02193022 |
Phase 3 |
Miltefosine |
35 |
Double-blind Placebo Controlled Trial Using Pentoxifylline Associated With Pentavalent Antimony in Cutaneous Leishmaniasis |
Completed |
NCT01381055 |
Phase 2, Phase 3 |
Pentoxifylline;Placebo |
36 |
Therapeutic Gain of Adding the Immunomodulator Pentoxifylline to the Treatment of Cutaneous Leishmaniasis |
Completed |
NCT01464242 |
Phase 2, Phase 3 |
Meglumine antimonate;Placebo;Pentoxifylline |
37 |
Secondary Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients Using Pentamidine as a Prophylactic Agent: a Prospective Cohort Study |
Completed |
NCT01360762 |
Phase 3 |
Pentamidine |
38 |
A Randomized, Double-blind, Pivotal Phase 3 Study of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Alone Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama |
Completed |
NCT01790659 |
Phase 3 |
WR 279,396;Paromomycin |
39 |
Efficacy Study of Liposomal Amphotericin in Disseminated Leishmaniasis |
Completed |
NCT02025491 |
Phase 3 |
Liposomal Amphotericin B |
40 |
A Randomized, Safety, Immunogenicity & Efficacy Study of Autoclaved Leishmania Major Plus BCG vs. BCG (Double Blind) or Placebo (Open), in Healthy High Risk Iranian Volunteers With Positive Response to Leishmanin (LST>0) |
Completed |
NCT00429780 |
Phase 2, Phase 3 |
|
41 |
A Randomized, Safety, Immunogenicity & Efficacy Study of Autoclaved Leishmania Major Plus BCG vs. BCG (Double Blind) or Placebo (Open), in Healthy High Risk Iranian Volunteers With no Response to Leishmanin |
Completed |
NCT00429715 |
Phase 2, Phase 3 |
|
42 |
Treatment of Bolivian Mucosal Leishmaniasis With Miltefosine, Pentavalent Antimony or Liposomal Amphotericin B |
Recruiting |
NCT04799236 |
Phase 3 |
Group 1: Miltefosine;Group 2: Pentavalent Antimony;Group 3: Liposomal amphotericin B |
43 |
Efficacy and Safety of Thermotherapy in Combination With Miltefosine Compared to Meglumine Antimoniate and Miltefosine Monotherapy for the Treatment of New World Cutaneous Leishmaniasis: A Phase III, Open Label, Multicenter Randomized Trial |
Recruiting |
NCT04515186 |
Phase 3 |
Meglumine Antimoniate;Miltefosine |
44 |
Randomised, Open Label, Multicentre, Non-inferiority Clinical Trial for New Treatment Modalities for Cutaneous Leishmaniasis Caused by Leishmania Tropica, in Pakistan |
Not yet recruiting |
NCT04268524 |
Phase 3 |
|
45 |
Effectiveness, Safety and Feasibility of Thermotherapy With the Hand-held Exothermic Crystallization Thermotherapy for Cutaneous Leishmaniasis (HECT-CL), Device for Cutaneous Leishmaniasis in Quetta, Pakistan |
Terminated |
NCT03208543 |
Phase 3 |
|
46 |
Open Label Randomized Study to Assess Safety and Efficacy of Azithromycin Versus Meglumine Antimoniate to Treat Cutaneous Leishmaniasis |
Terminated |
NCT00682656 |
Phase 2, Phase 3 |
Glucantime®;Zithromax ® |
47 |
Phase 3 Randomized Trial Comparing Fluconazole to Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis Caused by L. Braziliensis and L. Guyanensis |
Terminated |
NCT01953744 |
Phase 3 |
Fluconazole;Meglumine Antimoniate |
48 |
Double Blind, Randomized Controlled Trial, to Evaluate the Effectiveness of a Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis |
Terminated |
NCT00317629 |
Phase 3 |
controlled nitric oxide releasing patch;meglumine antimoniate |
49 |
Phase 2 Study of the Efficacy of Daylight Activated Photodynamic Therapy in the Treatment of Cutaneous Leishmaniasis |
Unknown status |
NCT00840359 |
Phase 2 |
|
50 |
EFFICACY AND SAFETY OF A SHORT COURSE OF THE COMBINATION OF MILTEFOSINE AND ANTIMONY TO TREAT CUTANEOUS LEISHMANIASIS IN BOLIVIA |
Unknown status |
NCT00537953 |
Phase 2 |
Miltefosine , meglumine antimoniate |
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
Antileishmanial [EPC]
Itraconazole
Ketoconazole
Meglumine
|
miltefosine
Pentamidine
Pentamidine Isethionate
|
Cochrane evidence based reviews: leishmaniasis
|